News Digest / Income Statements / Paysign Reports Q2 2025: Strong Revenue and Net Income Growth Despite Plasma Revenue Challenges

Paysign Reports Q2 2025: Strong Revenue and Net Income Growth Despite Plasma Revenue Challenges

StockInvest.us
09:06am, Wednesday, Aug 06, 2025
Illustration by StockInvest.us

Paysign, Inc. (NASDAQ: PAYS) has released its quarterly report for the period ending June 30, 2025, showing significant growth in net income and revenues despite challenges in some business segments.

Positive Aspects:

  • Revenue Growth: Total revenues for Q2 2025 reached $19,078,353, a 33.1% increase compared to $14,331,599 in Q2 2024.
  • Strong Pharma Performance: Revenues from the pharma industry surged to $7,753,906, up from $2,674,901, marking a substantial increase of 189.9%.
  • Net Income Increase: Net income for the quarter climbed to $1,387,761, nearly double the $697,102 recorded in Q2 2024.
  • Improved Gross Margin: Gross profit increased by 55%, and the gross margin percentage reached 61.6% compared to 52.9% in the previous year.
  • Cost Management: Despite an increase in operating expenses, the growth in revenues outpaced these costs, leading to significant operational profit.

Negative Aspects:

  • Decline in Plasma Revenue: Plasma industry revenues fell by 4.7% to $10,743,924, attributed to a decrease in plasma donations as inventory levels normalized.
  • Increasing Operating Expenses: Selling, general, and administrative expenses rose to $8,197,461, a 36.2% increase from the previous year, driven by higher labor costs and technology investments.
  • Cash Flow Issues: The company reported cash used in operations of $2,392,276 for the first half of 2025, contrasting sharply with the positive cash flow of $28,796,693 in the same period of 2024.

Key Statistics:

  • Q2 2025 Revenues: $19,078,353
  • Net Income Q2 2025: $1,387,761
  • Gross Margin Q2 2025: 61.6%
  • Basic Net Income per Share: $0.03
  • Number of Shares Outstanding: 54,451,888 as of July 31, 2025
  • Cash and Restricted Cash: $113,913,123 as of June 30, 2025

Overall, Paysign, Inc. shows promising growth particularly in the pharma segment, indicating strong demand for their services despite challenges in certain areas. The company's strategy appears focused on leveraging technology and expanding their service offerings to enhance revenue streams.

About The Author

StockInvest.us

StockInvest.us is a stock market research tool that provides daily stock signals and technical analysis for over 25 000 tickers on 38 exchanges. The company was founded in 2016 in Vilnius, Lithuania.

Trusted Broker
Start Your Journey With:
eToro
0% Commission Stock Trading
Follow Other Investors Strategy
Wide variety: Crypto, stocks, ETFs

Securities trading offered by eToro USA Securities, Inc. (“the BD”), member of FINRA and SIPC. Cryptocurrency offered by eToro USA LLC (“the MSB”) (NMLS: 1769299) and is not FDIC or SIPC insured. Investing involves risk.